Print
|
Close
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Active:
Yes
Cancer Type:
Solid Tumor
Unknown Primary
NCT ID:
NCT04185883
Trial Phases:
Phase I
Protocol IDs:
20190135 (primary)
NCI-2020-00134
2023-506794-35
Eligibility:
18 - 100 Years, Male and Female
Study Type:
Treatment
Study Sponsor:
Amgen, Inc.
NCI Full Details:
http://clinicaltrials.gov/show/NCT04185883
Summary
To evaluate the safety and tolerability of sotorasib administered in investigational
regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.